1. Home
  2. PMTS vs MGNX Comparison

PMTS vs MGNX Comparison

Compare PMTS & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CPI Card Group Inc.

PMTS

CPI Card Group Inc.

N/A

Current Price

$25.95

Market Cap

300.1M

Sector

Finance

ML Signal

N/A

Logo MacroGenics Inc.

MGNX

MacroGenics Inc.

N/A

Current Price

$2.42

Market Cap

262.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PMTS
MGNX
Founded
2007
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Finance Companies
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
300.1M
262.4M
IPO Year
2015
2013

Fundamental Metrics

Financial Performance
Metric
PMTS
MGNX
Price
$25.95
$2.42
Analyst Decision
Strong Buy
Buy
Analyst Count
4
7
Target Price
★ $32.50
$8.00
AVG Volume (30 Days)
124.5K
★ 904.5K
Earning Date
11-04-2026
11-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
★ 0.34
N/A
Revenue
★ $312,189,000.00
$149,500,000.00
Revenue This Year
$11.19
N/A
Revenue Next Year
$8.16
N/A
P/E Ratio
$77.24
★ N/A
Revenue Growth
★ 12.27
N/A
52 Week Low
$10.81
$1.29
52 Week High
$31.25
$5.08

Technical Indicators

Market Signals
Indicator
PMTS
MGNX
Relative Strength Index (RSI) 50.83 31.85
Support Level $24.36 $1.64
Resistance Level $26.23 $3.46
Average True Range (ATR) 0.88 0.32
MACD -0.01 -0.09
Stochastic Oscillator 38.54 26.39

Price Performance

Historical Comparison
PMTS
MGNX

About PMTS CPI Card Group Inc.

CPI Card Group Inc is a payment technology company engaged in providing financial payment card solutions and services. It offers credit, debit, and prepaid cards. The business segments of the group are Debit and Credit segment, which principally produce secure debit and credit cards and provide card services for U.S. card-issuing financial institutions, including personalization, instant issuance and other payment solutions such as digital push provisioning for mobile wallets; Prepaid Debit, which provides secure packaging solutions, Prepaid Debit Cards, and other integrated prepaid card services to prepaid program managers in the U.S.; and other: principally corporate expenses. The firm generates key revenue from Debit and Credit segment.

About MGNX MacroGenics Inc.

Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.

Share on Social Networks: